Immunic Psoriasis Analysis Adds Dose Of Uncertainty To Program

 
• By Alaric DeArment
  
Immunic announced an interim analysis of its Phase Ib study of IMU-935 in psoriasis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business